Drugs / SOM0226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02191826 | Jul 2014 → Nov 2015 | familial amyloid neuropathy | SOM Innovation Biotech SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2016-04-09 | SOM Innovation Biotech SA | Results SOM0226 DRUG ON NATURE COMMUNICATIONS sombiotech.com ↗
SOM0226 (tolcapone) is a strong candidate for therapeutic intervention in the TTR Amyloidosis variants, including those affecting the central nervous system, for which no small-molecule therapy exists. |
| 2015-11-17 | SOM Innovation Biotech SA | Results Phase IIA clinical trial for ttr amyloidosis successfully completed sombiotech.com ↗
Results show excellent drug efficacy and safety in patients for the treatment of this rare disease. |
| 2015-11-05 | SOM Innovation Biotech SA | Results 1ST PRIZE AT FIRST EUROPEAN CONGRESS ON HEREDITARY ATTR sombiotech.com ↗
During the event, preliminary results of the Phase 2a clinical trial with SOM0226 on ATTR Amyloidosis, which has recently been successfully completed, were presented. |
| 2014-07-05 | SOM Innovation Biotech SA | Regulatory SOM BIOTECH OBTAINS THE APPROVAL FROM REGULATORY AUTHORITIES TO CARRY OUT THE PHASE IIA CLINICAL TRIAL FOR TTR AMYLOIDOSIS sombiotech.com ↗
SOM Biotech has just obtained the approval from the Ethics Committee of Hopital Vall d’Hebron and the Spanish Medicines Agency (AEMPS) to start the Phase IIa clinical trial of its compound SOM0226 indicated for transthyretin Amyloidosis. |
| 2014-01-17 | SOM Innovation Biotech SA | Regulatory Orphan drug designation for SOM0226 sombiotech.com ↗
SOM Biotech announces Orphan Drug Designation in US for SOM0226, a compound for the treatment of Transthyretin Amyloidosis (ATTR). |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOM0226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02191826 ↗ |
| Known as | tolcapone | “Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers:...” PMID 31119947 ↗ May 2019 |
| Route | Oral | “Oral” NCT02191826 ↗ |
| Target | TTR | “to evaluate the TTR stabilization activity of SOM0226” NCT02191826 ↗ |